| Description |
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer[1].
|
| Related Catalog |
|
| In Vitro |
MGD009 (MGD009) 结合人和食蟹猴 CD3 和 B7-H3，对人 CD3ε/δ、食蟹猴 CD3ε/δ、人 B7-H3-His 和食蟹猴 B7-H3-His 的 KD 值分别为 13.9、14.7、24.6 和 30.2 nM[1]。 Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, 和 Detroit562 细胞) 介导多种 B7-H3 表达肿瘤细胞系的重定向杀伤[1]。 Obrindatamab (0.01-1000 ng/mL；PBMC 和 A498 细胞) 介导的 T 细胞活化和增殖具有靶抗原依赖性[1]。
|
| In Vivo |
Obrindatamab (MGD009; 0.004-1 mg/kg; i.v.) 抑制人 T 细胞或 PBMC 重建小鼠中表达 B7-H3 的肿瘤异种移植物的生长和肿瘤消退[1]。 Animal Model: NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m-/- mice, Established tumor model in human T-cell reconstituted MHC1-/- mice[1] Dosage: 0.004-1 mg/kg Administration: intravenous injection Result: Had antitumor activity in multiple in vivo models.
|
| References |
[1]. Paul M, et, al. MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors.
|
